Compare AbbVie Inc (ABBV) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? AbbVie Inc trades at $254 (market cap $449.91B), while ProShares UltraPro Short QQQ ETF trades at $40.35. The key difference: AbbVie Inc pays a 2.72% dividend while ProShares UltraPro Short QQQ ETF pays none, and AbbVie Inc is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | SQQQ | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $261.07 | $97.65 |
52-Week Low | $184.85 | $36.31 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
SQQQ (ProShares UltraPro Short QQQ ETF) declined 4.18% to $38.28, reflecting its bearish inverse leverage strategy against the Nasdaq-100. Technical indicators show a predominantly bearish signal with moving averages indicating strong selling pressure. The ETF's structure as a daily -3x leveraged product creates inherent decay risks, with historical data showing significant long-term value erosion. Recent news highlights concerns about SQQQ's suitability as a long-term investment vehicle.
SQQQ faces structural headwinds from daily reset mechanisms that compound losses in rising markets. While potentially useful for short-term tactical bearish bets, the ETF's design makes it unsuitable for buy-and-hold strategies. Investors seeking Nasdaq-100 exposure should consider the significant risks of value decay and timing sensitivity inherent in leveraged inverse products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
